本人所在科研团队为吴润晖主任率领的儿童出凝血疾病专业团队，该团队主要专注于儿童血友病、免疫性血小板减少及血栓性疾病的临床诊疗及临床相关的基础科学研究。该团队于2001年率先在全国开展儿童血友病诊疗工作，2006年组建了综合治疗团队、目前是已经有近20名专业成员组成的多专业（儿童血液、实验室、护理、放射、康复、药学等）的血友病综合诊疗中心，团队设有专业的血友病、ITP、血栓专病门诊及专业病房，实验室具备完善的出凝血专业诊断平台及基础科研平台；团队目前研究生导师2名，6人学术委员会任职共计39人次，3人担任专业杂志的编委、副编辑等任职；近10年承担科研项目23项；牵头或参与临床试验41项；发表科研论文几百余篇，2021年度发表论文21篇（SCI 10篇）；近5年牵头/参与制定专家共识/指南等12项。目前出凝血团队已培养毕业硕士研究生17名，毕业博士研究生4名，在读硕士研究生8名，在读博士研究生8名。

作为项目负责人主持的科研项目：

1.  国家自然科学基金面上项目，8197011，FOXO1/FOXO3a介导的调节性T细胞异常在儿童ITP慢性化转归中的机制研究，2020/01-2023/12，55万元，在研， 主持

2.  北京市自然科学基金面上项目，7192064，mTOR/S6K1/HIF-1a介导Treg/Th17轴失衡与儿童ITP慢性化，2019/01-2021/12，20万元，已结题，主持

3.  北京市自然科学基金面上项目，7152053，TPO/HIF-1α/RORγt信号通路介导的儿童ITP的Th17细胞分化机制，2015/01 -2017/12，15万元，已结题，主持

4.  诺和诺德中国血友病研究基金，The role of the imbalance of Th17/Treg axis in inhibitor development in children with severe hemophilia A，2014/01-2015/12，60万元，已结题，主持

5.  国家自然科学基金青年科学基金项目，81200351、HIF-1α在儿童免疫性血小板减少症Th17/Treg失衡中的作用及机制研究、2013/01-2015/12、23万元、已结题、主持

6.  北京市自然科学基金面上项目，7112050、调节性T细胞FOXP3去甲基化又要ITP免疫耐受及其机制、2011/01 -2013/12、11万元、 已结题、主持

近5年以第一作者或责任作者（含并列）发表的科研论文：（责任作者姓名后加*号，并列第一作者姓名后加“#”号）

1.    Hao Gu#, Zhenping Chen#(并列第一), Jie Ma, Jingyao Ma, Lingling Fu, RuiZhang, Tianyou Wang*, Runhui Wu*; Case report: Effectiveness of sirolimus in ade novo FAS mutation leading to autoimmune lymphoproliferative syndrome-FAS andelevated DNT/Treg ratio. Frontiers in pediatrics 2022;10:868193doi:10.3389/fped.2022.868193

2.    Kun Huang#, Di Ai#, Gang Li,Yingzi Zhen, Yan Wang, Ningning Zhang, Aihua Huo, Guoqing Liu, Zhenping Chen*（并列通讯）, Runhui Wu*;Individualised prophylaxis based on personalised target trough FVIII leveloptimised clinical outcomes in paediatric patients with severe haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia 2022Jul 18; doi:10.1111/hae.14635

3.    Jie Sun#, Zekun Li#, Kun Huang,Di Ai, Gang Li, Xingjuan Xie, Hao Gu, Guoqing Liu, Yingzi Zhen, Zhenping Chen*（并列通讯）, Runhui Wu*; F8gene mutation spectrum in severe hemophilia A with inhibitors: A large cohortdata analysis from a single center in China. Research and practice inthrombosis and haemostasis 2022 May;6(4):e12723 doi:10.1002/rth2.12723

4.    Hao Gu#, Xingjuan Xie#, JingyaoMa, Lingling Fu, Jie Ma, Runhui Wu*, ZhenpingChen*（并列通讯）; Single Nucleotide Polymorphisms of the HIF1A Gene are AssociatedWith Sensitivity of Glucocorticoid Treatment in Pediatric ITP Patients. Journalof pediatric hematology/oncology 2022 May 04; doi:10.1097/MPH.0000000000002483 

5.    Kun Huang#, Yan Wang#, YingziZhen, Gang Li, Xinyi Wu, Ningning Zhang, ZhenpingChen*（并列通讯）, Runhui Wu*; Inter-individual variability in pharmacokinetics andclinical features in pediatric patients with severe hemophilia A. Thrombosisresearch 2022 05;213:71-77 doi:10.1016/j.thromres.2022.03.008

6.    Kun Huang#, Yingzi# Zhen, GangLi, Xinyi Wu, Zhenping Chen*（并列通讯）, Runhui Wu*;Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A afterswitching to Kovaltry from other standard half-life factor VIII concentrates.Research and practice in thrombosis and haemostasis 2022 Feb;6(2):e12686doi:10.1002/rth2.12686 

7.    Hao Gu#, Zhenping Chen#(并列第一), Xiaodong Shi, Hong Cui, XuanguangQin, Huimin Hu, Jingyao Ma, Lingling Fu, Jie Ma, Tianyou Wang*, Runhui Wu*;Increased proportion of Th17/Treg cells at the new diagnosed stage of chronicimmune thrombocytopenia in pediatrics: the pilot study from a multi-center.European journal of pediatrics 2021 Nov;180(11):3411-3417 doi:10.1007/s00431-021-04121-z

8.    Huang Kun, Weiqun Xu, Min Zhou,Xiaojing Li, Zhongjin Xu, Yongjun Fang, Changgang Li, Zhenping Chen*（并列通讯）, Runhui Wu*; Pharmacokinetics and complementary evaluationsystem-based guidance on prophylaxis of paediatric patients with haemophilia Ain China with Kovaltry: protocol of the LEAP study. BMJ open 2021 0705;11(7):e048432 doi:10.1136/bmjopen-2020-048432

9.    Kun Huang, Yingzi Zhen, GangLi, Xinyi Wu, Zhenping Chen*（并列通讯）, Runhui Wu*;Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatricpatients with severe haemophilia A. Haemophilia : the official journal of theWorld Federation of Hemophilia 2021 Jul;27(4):e450-e457 doi:10.1111/hae.14336

10.  Kun Huang#, Yingzi Zhen#, GangLi, Xinyi Wu, Runhui Wu, Zhenping Chen*(通讯作者); Pharmacokinetic study of Kovaltry in thirty-five pediatricpatients aged <12 years with severe hemophilia A. Haemophilia : the officialjournal of the World Federation of Hemophilia 2021 May;27(3):e340-e346doi:10.1111/hae.14276

11.  Zhenping Chen#, Kun Huang#, Gang Li,Yingzi Zhen, Xinyi Wu, Ai Di, Guoqing Liu, Zekun Li, Iorio Alfonso, Runhui Wu;Pharmacokinetic variability of factor VIII concentrates in Chinese pediatricpatients with moderate or severe hemophilia A. Pediatric investigation 2021Mar;5(1):38-45 doi:10.1002/ped4.12252

12.  Kun Huang, Gang Li, YingziZhen, Xinyi Wu, Zhenping Chen*（并列通讯）, Runhui Wu*;Comparative pharmacokinetics of Kogenate FS and Kovaltry in 14 Chinesepaediatric patients with haemophilia A: A single-centre study. Haemophilia : theofficial journal of the World Federation of Hemophilia 2021 Mar;27(2):e287-e290doi:10.1111/hae.14163

13.  Hao Gu#, Zhenping Chen#(并列第一), Jie Ma, Jing Wang, Rui Zhang, RunhuiWu, Tianyou Wang; Sirolimus is effective in autoimmune lymphoproliferativesyndrome-type III: A pedigree case report with homozygous variation PRKCD.International journal of immunopathology and pharmacology 2021Jan-Dec;35:20587384211025934 doi:10.1177/20587384211025934

14.  Yeling Lu#, Zhenping Chen#(并列第一), Jing Dai#, Xi Wu, Hao Gu, Zekun Li,Jian Li, Qiulan Ding, Wenman Wu*, Runhui Wu*, Xuefeng Wang*; Maternalmicrochimerism protects hemophilia A patients from inhibitor development. Bloodadvances 2020 May 12;4(9):1867-1869 doi:10.1182/bloodadvances.2020001832

15.   Zhenxing Guo#*, Zhenping Chen#(并列第一), Yaru Xu, Yu Zhang, LiangdingHu, Fan Yu, Junyue Chai, Li Liu, Xiuhong Ren; The Association of Circulating TFollicular Helper Cells and Regulatory Cells with Acute Myeloid LeukemiaPatients. Acta haematologica 2020;143(1):19-25 doi:10.1159/000500588

16.  Zhen-Ping Chen, Pei-Jing Li, Gang Li,Ling Tang, Ying-Zi Zhen, Xin-Yi Wu, Xiao-Ling Cheng, Koon Hung Luke, Victor SBlanchette, Man-Chiu Poon, Qiu-Lan Ding, Run-Hui Wu*; Pharmacokinetic Studiesof Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.Chinese medical journal 2018 Aug 05;131(15):1780-1785doi:10.4103/0366-6999.233604

17. 陈慧,马洁,邢天禹,赵晓曦、田硕、高超、陈振萍*. 重型再生障碍性贫血患儿免疫抑制治疗疗效及T细胞亚群变化的临床分析[J]. 国际输血及血液学杂志,2022,45(3):229-237. DOI:10.3760/cma.j.cn511693-20211113-00229.

18. 陈振萍,刘葳,蔡力生.药物代谢动力学指导血友病A治疗的中国专家共识[J].中国临床研究,2021,34(05):577-581+591.DOI:10.13429/j.cnki.cjcr.2021.05.001.

19.  谢幸娟,陈振萍*.儿童免疫性血小板减少症发病机制研究进展[J].中国实用儿科杂志,2021,36(02):90-94.DOI:10.19538/j.ek2021020603.

20. 陈振萍,李刚,李泽坤,甄英姿,黄昆,吴润晖*.艾美赛珠单抗对血友病A凝血试验检测的影响[J].临床血液学杂志,2020,33(11):771-775.DOI:10.13201/j.issn.1004-2806.2020.11.009.

21. 陈慧,陈振萍*.获得性再生障碍性贫血免疫异常机制的研究进展[J].国际输血及血液学杂志,2019,42(3):244-248. DOI:10.3760/cma.j.issn.1673-419X.2019.03.012.

22. 陈慧,刘怡,马洁,高超,邢天禹,赵晓曦,陈振萍*.免疫抑制治疗对儿童重型再生障碍性贫血细胞因子表达的影响[J].中国循证儿科杂志,2019,14(06):460-463